These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
508 related articles for article (PubMed ID: 16672926)
1. Therapeutic implications of the gender-specific aspects of cardiovascular disease. Regitz-Zagrosek V Nat Rev Drug Discov; 2006 May; 5(5):425-38. PubMed ID: 16672926 [TBL] [Abstract][Full Text] [Related]
2. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Jochmann N; Stangl K; Garbe E; Baumann G; Stangl V Eur Heart J; 2005 Aug; 26(16):1585-95. PubMed ID: 15996977 [TBL] [Abstract][Full Text] [Related]
3. [Sex differences and cardiovascular drugs]. Løchen ML; Kvan E Tidsskr Nor Laegeforen; 2010 Feb; 130(4):382-4. PubMed ID: 20220863 [TBL] [Abstract][Full Text] [Related]
4. New perspectives on Mars and Venus: unravelling the role of androgens in gender differences in cardiovascular biology and disease. Ng MK Heart Lung Circ; 2007 Jun; 16(3):185-92. PubMed ID: 17448726 [TBL] [Abstract][Full Text] [Related]
5. Gender-specific implications for cardiovascular medication use in the elderly optimizing therapy for older women. Schwartz JB Cardiol Rev; 2003; 11(5):275-98. PubMed ID: 12943605 [TBL] [Abstract][Full Text] [Related]
11. Molecular and cellular basis of cardiovascular gender differences. Mendelsohn ME; Karas RH Science; 2005 Jun; 308(5728):1583-7. PubMed ID: 15947175 [TBL] [Abstract][Full Text] [Related]
12. FGF21: a novel prospect for the treatment of metabolic diseases. Kharitonenkov A; Shanafelt AB Curr Opin Investig Drugs; 2009 Apr; 10(4):359-64. PubMed ID: 19337957 [TBL] [Abstract][Full Text] [Related]
13. Gender differences in coronary artery disease: review of diagnostic challenges and current treatment. Gopalakrishnan P; Ragland MM; Tak T Postgrad Med; 2009 Mar; 121(2):60-8. PubMed ID: 19332963 [TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomics and cardiovascular drugs: need for integrated biological system with phenotypes and proteomic markers. Siest G; Marteau JB; Maumus S; Berrahmoune H; Jeannesson E; Samara A; Batt AM; Visvikis-Siest S Eur J Pharmacol; 2005 Dec; 527(1-3):1-22. PubMed ID: 16316654 [TBL] [Abstract][Full Text] [Related]
15. Cardiovascular disease prevention in women: Impact of dietary interventions. Hoekstra T; Beulens JW; van der Schouw YT Maturitas; 2009 May; 63(1):20-7. PubMed ID: 19307070 [TBL] [Abstract][Full Text] [Related]
16. New therapeutic agents marketed in 1995. Hussar DA Pa Med; 1996 Apr; 99(4):43-6. PubMed ID: 8935886 [TBL] [Abstract][Full Text] [Related]
17. Using measures of disease progression to determine therapeutic effect: a sirens' song. Granger CB; McMurray JJ J Am Coll Cardiol; 2006 Aug; 48(3):434-7. PubMed ID: 16875965 [TBL] [Abstract][Full Text] [Related]
18. Cardiovascular disease strategies--directions after the human genome. Barone FC Curr Opin Investig Drugs; 2006 Sep; 7(9):789-91. PubMed ID: 17002255 [No Abstract] [Full Text] [Related]
19. Adverse drug reactions induced by cardiovascular drugs in cardiovascular care unit patients. Mohebbi N; Shalviri G; Salarifar M; Salamzadeh J; Gholami K Pharmacoepidemiol Drug Saf; 2010 Sep; 19(9):889-94. PubMed ID: 20146242 [TBL] [Abstract][Full Text] [Related]
20. More reasons why men and women are not the same (gender differences in electrophysiology and arrhythmias). Yarnoz MJ; Curtis AB Am J Cardiol; 2008 May; 101(9):1291-6. PubMed ID: 18435960 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]